Selective bone targeting 5-fluorouracil prodrugs: synthesis and preliminary biological evaluation

Bioorg Med Chem. 2011 Jun 15;19(12):3750-6. doi: 10.1016/j.bmc.2011.05.004. Epub 2011 May 8.

Abstract

Bone tumor is a notoriously difficult disease to manage, requiring frequent and heavy doses of systemically administered chemotherapy. Targeting anticancer drug to the bone after systemic administration may provide both greater efficacy of treatment and less frequent administration. In this paper, a series of bone targeting Asp oligopeptides 5-fluorouracil conjugates have been synthesized in a convergent approach and well characterized by NMR and MS techniques. Their hydroxyapatite (HAP) affinity, drug release and cytotoxicity characteristics were evaluated in in vitro conditions. All the prodrugs were water soluble and exhibited high affinity to HAP .The efficient release of the active drug moiety occurring by the cleavage of different linkage in physiological conditions significantly reduced the number of viable human cancer cells. From in vivo distribution, we get these compounds with high bone-selectivity and long halflife. These results provided an effective entry to the development of new bone targeting chemotherapeutic drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • Bone Neoplasms / drug therapy
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Chromatography, High Pressure Liquid
  • Drug Delivery Systems
  • Fluorouracil / chemical synthesis
  • Fluorouracil / chemistry
  • Fluorouracil / pharmacokinetics
  • Fluorouracil / pharmacology*
  • Humans
  • Mice
  • Molecular Structure
  • Prodrugs

Substances

  • Antineoplastic Agents
  • Prodrugs
  • Fluorouracil